The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer – study protocol

Suzanne van der Gaag, André Vis, Imke Bartelink, Harry Hendrikse, Daniela E Oprea-Lager · 2026

Read The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer – study protocol by Suzanne van der Gaag, André Vis, Imke Bartelink, Harry Hendrikse, Daniela E Oprea-Lager (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289025.txt.

Description

Suzanne van der Gaag and colleagues sketch a 2026 trial plan on prostate scans. The DARO-flare trial sits at one Dutch center. It deals with hormone-sensitive prostate cancer. A drug called darolutamide may boost scan signals. That boost is called a PSMA flare.

Men with few spread spots after past cure will join. Half will take the drug for seven days. Half will take it for 14 days. All will get scans at the start. Repeat scans will run on days 7 and 14. The main check is change in spot counts. Care changes and side effects will also be logged.

Catalog record

CREATORSuzanne van der Gaag, André Vis, Imke Bartelink, Harry Hendrikse, Daniela E Oprea-Lager
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26887
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13289025

Browse the full library · About the Tower of Babel